An update to the American Cancer Society (ACS) guideline regarding screening for the early
detection of cervical precancerous lesions and cancer is presented. The guidelines are …

Patients and clinicians experience the frustration of cutaneous viral warts caused by
infection with the human papilloma virus (HPV). Warts appear in various forms on different …

A group of 146 experts representing 29 organizations and professional societies met
September 18-19, 2006, in Bethesda, MD, to develop revised evidence-based, consensus …

Background The cost-effectiveness of prophylactic vaccination against human
papillomavirus types 16 (HPV-16) and 18 (HPV-18) is an important consideration for …

Objective. To provide revised evidence-based consensus guidelines for managing women
with abnormal cervical cancer screening test results. Participants. A group of 146 experts …

Objective To assess the cost effectiveness of including preadolescent boys in a routine
human papillomavirus (HPV) vaccination programme for preadolescent girls. Design Cost …

OBJECTIVE: To conduct a cost-effectiveness analysis of opportunistic salpingectomy
(elective salpingectomy at hysterectomy or instead of tubal ligation). METHODS: A Markov …

Background The availability of human papillomavirus (HPV) DNA testing and vaccination
against HPV types 16 and 18 (HPV-16, 18) motivates questions about the cost-effectiveness …

PURPOSE: In a population-based sample of cervical cancer survivors, health-related quality
of life (HRQoL) was assessed 2–10 years postdiagnosis. METHODS AND MATERIALS: All …

The policy recommends cytology-based screening every three years from 25 to 30 years of
age, followed by HPV-based screening every five years from 30 to 65 years of age (Exhibit …